Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail
-

FDA Drug Safety Newsletter - Volume 2, Number 1, 2009

This publication provides postmarketing information to healthcare professionals to enhance communication of new drug safety information, raise awareness of reported adverse events, and stimulate additional adverse event reporting.
    

In This Issue
 

Editor's Note

Postmarket Reviews

Reports of suicidality associated with use of varenicline (marketed as CHANTIX) and bupropion (marketed as ZYBAN and GENERICS

Information for healthcare professionals on an abacavir (marketed as ZIAGEN, EPZICOM, and TRIZIVIR) hypersensitivity reaction, HLA-B*5701, and skin patch testing

Reports of serious liver injury associated with use of atomoxetine (marketed as STRATTERA)

FDA Patient Safety News

Drug Safety Communications

List of drug safety advisories posted on FDA’s Web site from September 1, 2008 through November 30, 2008, with related links

 PDF version of Drug Safety Newsletter

U.S. Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
5600 Fishers Lane, Rockville MD 20857-0001
Phone: 1-888-INFO-FDA (1-888-463-6332)

Acknowledgments:
Office of Surveillance and Epidemiology and Office of New Drugs

Renan A. Bonnel, PharmD, MPH
Senior Scientific Editor

Gregory D. Busse, PhD
Editor

Contributing Authors:
Martin Pollock, PharmD, Joann H. Lee, PharmD (varenicline and bupropion)
Ida-Lina Diak, PharmD, John Senior, MD (atomoxetine)
Wendy Carter, MD, Kendall Marcus, MD (abacavir)

Art Direction and Design: Elena H. Ketelhut

We value your comments. Please let us know by reaching us at Comments. All text in the Drug Safety Newsletter is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.
-
-